Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

CHR. OLESEN PHARMACEUTICALS A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1%   Bankruptcy risk   6.1% 4.8% 3.4% 3.8% 6.1% 5.9% 12.8% 10.6%   Credit score (0-100)   40 46 55 51 37 39 17 23   Credit rating   BBB BBB BBB BBB BBB BBB BB BB   Credit limit (kEUR)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kEUR)  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   529 468 1,069 1,026 740 1,215 0.0 0.0   EBITDA   316 245 798 719 446 740 0.0 0.0   EBIT   272 205 758 679 406 740 0.0 0.0   Pre-tax profit (PTP)   170.0 129.0 612.9 584.3 322.1 597.4 0.0 0.0   Net earnings   128.0 95.8 474.9 454.8 251.1 465.2 0.0 0.0   Pre-tax profit without non-rec. items   170 129 613 584 322 597 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kEUR)  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Tangible assets total   160 120 80.0 40.0 0.0 0.0 0.0 0.0   Shareholders equity total   -126 -30.5 444 599 850 1,316 1,236 1,236   Interest-bearing liabilities   3,153 5,366 6,524 7,385 11,099 11,615 0.0 0.0   Balance sheet total (assets)   3,507 6,868 8,388 9,414 12,958 14,986 1,236 1,236   Net Debt   3,152 5,366 6,524 7,385 11,097 11,523 -1,236 -1,236     See the entire balance sheet 1000.0 Volume  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   529 468 1,069 1,026 740 1,215 0.0 0.0   Gross profit growth   33.7% -11.5% 128.5% -4.0% -27.9% 64.2% -100.0% 0.0%   Employees   1 1 1 1 1 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,507 6,868 8,388 9,414 12,958 14,986 1,236 1,236   Balance sheet change%   -16.0% 95.9% 22.1% 12.2% 37.7% 15.6% -91.8% 0.0%   Added value   271.9 205.3 757.6 679.0 406.0 740.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -89 -80 -80 -80 -80 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   51.5% 43.9% 70.9% 66.2% 54.8% 60.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   6.8% 4.5% 10.2% 8.6% 4.2% 6.1% 0.0% 0.0%   ROI %   8.7% 5.5% 12.6% 10.2% 4.7% 6.9% 0.0% 0.0%   ROE %   3.3% 1.8% 13.0% 87.2% 34.6% 43.0% 0.0% 0.0%   1000.0 Solidity  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Equity ratio %   -3.5% -0.4% 5.3% 6.4% 6.6% 8.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   996.1% 2,187.3% 817.9% 1,027.0% 2,487.9% 1,556.1% 0.0% 0.0%   Gearing %   -2,495.5% -17,592.8% 1,468.0% 1,232.5% 1,305.3% 882.9% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3.3% 2.5% 2.8% 2.5% 1.6% 2.3% 0.0% 0.0%   1000.0 Liquidity  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Quick Ratio   0.6 0.4 0.7 0.7 0.7 0.8 0.0 0.0   Current Ratio   0.9 1.0 1.0 1.1 1.1 1.1 0.0 0.0   Cash and cash equivalent   0.5 0.1 0.3 0.1 2.4 92.4 0.0 0.0   1000.0 Capital use efficiency  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -275.6 -139.4 371.1 559.2 850.3 1,315.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2017 2017/9 2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023e N/A 2024e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   272 205 758 679 406 370 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   316 245 798 719 446 370 0 0   EBIT / employee   272 205 758 679 406 370 0 0   Net earnings / employee   128 96 475 455 251 233 0 0